New trial aims to outsmart superbug in ICU patients

NCT ID NCT06440304

Recruiting now Disease control Sponsor: Clinical Hospital Centre Zagreb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests three different antibiotic combinations to treat a dangerous, drug-resistant bacteria called CRAB that causes infections in intensive care patients. Researchers will compare colistin combined with either fosfomycin, ampicillin/sulbactam, or eravacycline in 108 surgical ICU patients. The goal is to find which combination clears the infection fastest and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: colistin combined with either fosfomycin, ampicillin/sulbactam, or eravacycline
What this could lead to: If successful, this could identify the most effective antibiotic combination for treating drug-resistant CRAB infections in ICU patients, potentially improving survival and reducing hospital stays.
What could go wrong: This is a relatively small trial (108 participants) and results may not apply to all patients. Antibiotic resistance is complex, and even the best combination may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acinetobacter infectious disease bacterial infectious disease bacterial infectious disease with sepsis Infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFECTIONS, BACTERIAL SEPSIS BACTERIAL

Contacts and locations

Locations

University Hospital Centre Zagreb
RECRUITING

Zagreb, 10000, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.